Transgene organise the Transgene’s R&D Day with the participation of world-leading scientists and clinicians about the Topic « Modulating the tumor micro-environment »: changing tumor physical properties, breaking immune tolerance, improving homing of effector T-cells.
Transgene’s team will provide you with an overview of their virus-based immunotherapies and innovation strategy. Their scientific and clinical partners will comment on the evolving landscape of immuno-oncology, and how Transgene’s approaches could address unmet medical needs.
- Philippe Archinard, Chairman and CEO
- Eric Quéméneur, Chief Scientific Officer
- Maud Brandely-Talbot, Chief Medical Officer
Please RSVP to firstname.lastname@example.org and indicate your name, company and email
A detailled event programm will be sent.